Macrogenics Inc
A biotech company that engineers antibody-based therapies to fight cancer. Its drug MARGENZA was approved in 2020 for HER2-positive breast cancer, and its DART platform builds proteins that bind two targets at once, steering immune cells toward tumors. Founded in 2000 in Rockville, Maryland, by a team of scientists, its name combines "macro," for the large protein molecules it builds, with "genics," echoing genetic engineering.
Sold 200.0K
Bought 3.90M
Granted 729.1K
Granted 162.9K · Bought 40.0K · Sold 50.0K
Granted 371.9K · Sold 171.7K
Granted 14.8K · Bought 100.0K
Granted 237.4K · Sold 136.7K
Granted 121.4K · Sold 69.1K
Bought 10.0K
Granted 14.8K · Bought 15.0K · Sold 308.5K
Granted 100.8K · Sold 36.8K
Granted 259.4K · Sold 190.8K
Granted 44.5K
Granted 155.0K · Sold 135.0K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 14.8K
Granted 8.0K · Sold 423
Granted 6.9K · Sold 6.9K
Granted 65.8K · Sold 68.7K
Granted 20.8K · Bought 46.9K · Sold 20.8K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Oronsky Arnold LDirector · 6 transactions | — | 9.94Mas of Feb 2014 | — | — | 200.0K |
| BB Biotech Ag +1 co-filer10% owner · 19 transactions | — | 9.93Mas of Oct 2023 | — | 3.90M | — |
| Cash Harvey B +8 co-filers10% owner · 5 transactions | — | 8.23Mas of Oct 2013 | — | — | — |
| Alta Biopharma Partners III GMBH & Co Beteiligungs KG +2 co-filers10% owner · 4 transactions | — | 6.94Mas of Oct 2013 | — | — | — |
| Bonderman David +2 co-filersFormer 10% Owner · 1 transaction | — | 2.21Mas of Oct 2013 | — | — | — |
| Koenig ScottDirector · 24 transactions | — | 867.2K | 729.1K | — | — |
| Karrels JamesSVP and CFO · 34 transactions | — | 206.0K | 162.9K | 40.0K | 50.0K |
| Bonvini EzioSr VP, Research & CSO · 67 transactions | — | 145.8K | 371.9K | — | 171.7K |
| Heiden William KDirector · 5 transactions | — | 114.8K | 14.8K | 100.0K | — |
| Risser Eric BlasiusPresident and CEO, Director · 87 transactions | — | 77.2K | 237.4K | — | 136.7K |
| Stein Kathryn ESVP, Product Dev. & Regulatory · 17 transactions | — | 63.2Kas of Jan 2016 | 121.4K | — | 69.1K |
| Costa Paulo FDirector · 1 transaction | — | 59.4Kas of Mar 2016 | — | 10.0K | — |
| Hurwitz EdwardDirector · 10 transactions | — | 47.8K | 14.8K | 15.0K | 308.5K |
| Spitznagel ThomasSr VP, Technical Ops · 24 transactions | — | 38.5K | 100.8K | — | 36.8K |
| Peters Jeffrey StuartSenior VP, GC, and Secretary · 36 transactions | — | 31.1K | 259.4K | — | 190.8K |
| Eck Stephen L.Chief Medical Officer · 6 transactions | — | 29.4Kas of Feb 2025 | 44.5K | — | — |
| Wigginton Jon MarcSr VP, Clinical Dev. & CMO · 37 transactions | — | 18.9Kas of Feb 2018 | 155.0K | — | 135.0K |
| Saran AtulSVP & General Counsel · 5 transactions | — | 17.0Kas of Apr 2017 | — | — | — |
| Chhabra MeenuDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Ferrante Karen JeanDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Jackson Scott ThomasDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Liu MargaretDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| O'Brien Federica F.Director · 3 transactions | — | 14.8K | 14.8K | — | — |
| Siegel Jay PhilipDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Stump David CDirector · 3 transactions | — | 14.8K | 14.8K | — | — |
| Smith Beth AnnVP, Controller & Treasurer · 10 transactions | — | 13.2K | 8.0K | — | 423 |
| Fust Matthew KDirector · 2 transactions | — | 7.4Kas of Feb 2019 | 6.9K | — | 6.9K |
| Cilinski LynnVP, Controller and Treasurer · 23 transactions | — | 6.2Kas of Feb 2024 | 65.8K | — | 68.7K |
| Galbraith KennethDirector · 8 transactions | — | 0as of Sep 2020 | 20.8K | 46.9K | 20.8K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +2.72M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.